CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
lapatinib +1 moredrug
Likely dose
lapatinib 1250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00574171
NCT00574171Phase 2Completed
CompareCT.gov

A Phase II Trial of Lapatinib and Capectiabine for Patients With Refractory Advanced Colorectal Adenocarcinoma (LAP109859)

University of Wisconsin, Madison·interventional·Posted Dec 17, 2007·Updated Dec 18, 2019

In Brief

A Phase 2 clinical trial evaluating lapatinib and Capecitabine for Metastatic Colorectal Cancer. Completed, enrolled 29 participants across 1 site.

Detailed Summary

The purpose of this study is to find out how effective this combination is as a second line treatment for colorectal cancer that has spread from one part of the body to another (metastasized) or has not metastasized but is considered inoperable (unable to be removed by surgery). The side effects and survival experienced by subjects receiving these drugs will also be evaluated. This is a phase II research study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Colorectal Cancer
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 17, 2007
Enrollment StartSep 1, 2007
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 18.5 years ago

Interventions

lapatinibdrug

1250mg by mouth daily one hour before or after breakfast on a continuous basis.

Capecitabinedrug

2000mg/m2 of body surface area (BSA), by mouth, divided into twice daily dosing. Capecitabine will be given for days 1 through 14 of a 21 day cycle.